STRO
STRO clinical trials: SUTRO BIOPHARMA, INC.
Every trial on ClinicalTrials.gov where SUTRO BIOPHARMA, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 8
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
STRO on the catalyst calendar · STRO registry changes
- Primary completion Feb 2028Sponsor estimatePhase 1NCT07807345Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticSutro Biopharma, Inc. · Head & Neck Squamous Cell CarcinomaRecruitingSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2025ActualPhase 1/Phase 2NCT06679582Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AMLSutro Biopharma, Inc. · Acute Myeloid Leukemia (AML)TerminatedSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1NCT07227168A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerSutro Biopharma, Inc. · Head and Neck Squamous Cell Carcinoma HNSCCRecruitingSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 26, 2025ActualPhase 2/Phase 3NCT05870748REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in...Sutro Biopharma, Inc. · Ovarian CancerTerminatedSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2025ActualPhase 1NCT05200364A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerSutro Biopharma, Inc. · Ovarian CancerTerminatedSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2025ActualPhase 2NCT06555263Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung CancerSutro Biopharma, Inc. · Lung CancerWithdrawnSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2024ActualPhase 1NCT03748186Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersSutro Biopharma, Inc. · Ovarian CancerCompletedSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2024ActualPhase 1NCT03424603Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesSutro Biopharma, Inc. · B-cell LymphomaCompletedSTROLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2025ActualPhase 1/Phase 2NCT06238687A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid TumorsTasly Pharmaceutical Group Co., Ltd · Neoplasm MalignantCompletedSTROCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner